Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Discussing Use of Data from “Specified Clinical Research” in Application Dossiers, Will Issue Preliminary Conclusions by March
August 29, 2018
- Chuikyo Might Take Up "Biosames" for Discussion Around Autumn: Ex-Pharmaceutical Management Director
August 28, 2018
- Japan Eyes State Funds to Boost Sakigake Review Staffers: FY2019 Budget Request
August 27, 2018
- MHLW to Expand MID-NET and Coordinate with Other Databases and Registries to Improve Safety Measures: Official
August 27, 2018
- It’s Too Early to Introduce Incentives for Biosimilar Use: MHLW Official
August 27, 2018
- MHLW to Issue Optimal Use Guidelines for Imfinzi, Might Make Changes on Latest Data
August 23, 2018
- MHLW Orders Label Revisions for 7 Flu Drugs Including Tamiflu
August 23, 2018
- Chuikyo Discusses ICER Evaluations for Drugs with Multiple Indications
August 23, 2018
- Chuikyo to Allow “Ranged” ICER Values in Cost-Effective Assessment
August 23, 2018
- Chuikyo Members Call for More Info Disclosure for CEA Scheme
August 23, 2018
- Chuikyo OKs Pricing of Entyvio, Imfinzi, Gazyva and More; Listing on Aug. 29
August 22, 2018
- MHLW OKs Opdivo’s Add’l Indications and Flat Dose, 1st-Line Tagrisso Use and More
August 22, 2018
- Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
- Impasse Continues over Mumps Vaccine Inclusion in Public Immunization Programs
August 20, 2018
- MHLW Panel to Review Kyorin’s OAB Drug Vibegron and More on Aug. 30
August 17, 2018
- MHLW Revving Up Biosimilar Drive with Educational Workshop for Healthcare Pros
August 17, 2018
- Astellas AML Drug, Pfizer’s Lorlatinib Up for MHLW Panel Review on Aug. 29
August 16, 2018
- Japan Approves Nesp “Biosame,” Eyes Riveted on December Listing
August 16, 2018
- Collaboration Research Project between Ministries Aims to Develop AI by FY2021 for Drug Discovery for Lung Cancer, IPF
August 16, 2018
- EFPIA Japan Proposes Establishing Organization Formed by Multiple Companies for Blood Collection Operation
August 10, 2018
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…